Whole‐exome sequencing and adrenocorticotropic hormone therapy in individuals with infantile spasms. (19th November 2021)

• Record Type: Journal Article
• Authors: Demarest, Scott; Calhoun, Jeff; Eschbach, Krista; Yu, Hung‐Chun; Mirsky, David; Angione, Katie; Shaikh, Tamim H; Carvill, Gemma L; Benke, Tim A
• Other Names: Geiger Elizabeth A investigator.; Gunti Jonathan investigator.; Vanderveen Gina investigator.
• Is Part Of: Developmental medicine & child neurology. Volume 64:Number 5(2022)
• Page Start: 633
• Page End: 640
• Publication Date: 2021-11-19
• Subjects: Child development -- Periodicals; Pediatric neurology -- Periodicals; 616.8
• DOI: 10.1111/dmcn.15109
• Languages: English
• ISSNs: 0012-1622

Abstract

Abstract : Aim: To identify additional genes associated with infantile spasms using a cohort with defined infantile spasms. Method: Whole‐exome sequencing (WES) was performed on 21 consented individuals with infantile spasms and their unaffected parents (a trio‐based study). Clinical history and imaging were reviewed. Potentially deleterious exonic variants were identified and segregated. To refine potential candidates, variants were further prioritized on the basis of evidence for relevance to disease phenotype or known associations with infantile spasms, epilepsy, or neurological disease. Results: Likely pathogenic de novo variants were identified in NR2F1, GNB1, NEUROD2, GABRA2, and NDUFAF5 . Suggestive dominant and recessive candidate variants were identified in PEMT, DYNC1I1, ASXL1, RALGAPB, and STRADA ; further confirmation is required to support their relevance to disease etiology. Interpretation: This study supports the utility of WES in uncovering the genetic etiology in undiagnosed individuals with infantile spasms with an overall yield of five out of 21. High‐priority candidates were identified in an additional five individuals. WES provides additional support for previously described disease‐associated genes and expands their already broad mutational and phenotypic spectrum.